Prothrombin Complex Concentrate Market Report 2026

The prothrombin complex concentrate market size has grown strongly in recent years. It will grow from $1.38 billion in 2025 to $1.48 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing prevalence of coagulation disorders, expansion of emergency care infrastructure, availability of plasma-derived therapies, rising surgical procedure volumes, growing use of anticoagulant medications.

The prothrombin complex concentrate market size is expected to see strong growth in the next few years. It will grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing demand for fast-acting coagulation therapies, rising investments in recombinant factor development, expansion of trauma care facilities, growing focus on patient safety in anticoagulant management, increasing adoption of standardized bleeding protocols. Major trends in the forecast period include increasing adoption of four-factor pcc products, rising use of pcc for rapid anticoagulant reversal, growing demand for emergency bleeding management solutions, expansion of recombinant coagulation products, enhanced focus on rapid-acting hemostatic therapies.

The rising prevalence of bleeding disorders is expected to drive the growth of the prothrombin complex concentrate market in the coming years. Bleeding disorders are medical conditions in which the blood fails to clot properly, resulting in excessive bleeding due to absent or dysfunctional clotting factors or platelets. The incidence of bleeding disorders is increasing largely because of the growing prevalence of inherited genetic conditions such as hemophilia, a rise in liver disease cases, increased use of anticoagulant medications, and a higher occurrence of vitamin K deficiencies. Prothrombin complex concentrate supports the management of bleeding disorders by rapidly restoring essential clotting factors required for effective coagulation and hemostasis. For example, in October 2024, according to a report by the World Federation of Hemophilia, a Canada-based nonprofit organization, there were 179,703 reported cases of hemophilia A worldwide in 2023. Of these, 162,040 cases, or 90%, were male patients, 6,990 cases were female patients, and 10,673 cases, or 6%, did not report patient sex. Therefore, the increasing prevalence of bleeding disorders is contributing to the expansion of the prothrombin complex concentrate market.

The increasing prescription rate of anticoagulants is also expected to propel the growth of the prothrombin complex concentrate market going forward. Anticoagulants are medications that prevent or reduce the formation of blood clots by inhibiting coagulation factors or platelet aggregation. The rise in anticoagulant prescriptions is driven by the growing prevalence of cardiovascular diseases, an aging population, broader clinical indications, improved screening programs, and advancements in anticoagulant therapies. Prothrombin complex concentrate is used to reverse the effects of anticoagulants by rapidly replenishing clotting factors and restoring hemostasis in patients experiencing severe bleeding or requiring urgent surgical intervention. For instance, in June 2025, according to the Northern Ireland Statistics and Research Agency, a UK-based government agency, 64,000 individuals received oral anticoagulants in 2024/25, representing a 3.8% increase compared to the previous year, with 3.3% of the population using these medications. Therefore, the growing use of anticoagulants is driving the growth of the prothrombin complex concentrate market.

Major companies operating in the prothrombin complex concentrate market are focusing on the development of innovative formulations, such as lyophilized powder, to improve product stability, extend shelf life, and simplify administration. Lyophilized powder formulations are freeze-dried to remove moisture, helping preserve potency and allowing for easier storage and rapid reconstitution in emergency situations. For example, in July 2023, Octapharma USA Inc., a US-based biotechnology company, received FDA approval for Balfaxar, a four-factor prothrombin complex concentrate intended for urgent warfarin reversal during surgeries and invasive procedures. The approval was supported by results from the LEX-209 trial, which demonstrated a 94.6% hemostatic efficacy, showing effectiveness comparable to Kcentra. This development highlights the industry’s emphasis on advancing coagulation therapies to improve patient outcomes in critical care environments.

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Takeda Pharmaceutical Company Limited, CSL Behring GmbH, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd BPL, Prothya Biosolutions B.V., China Biologic Products Holdings Inc., Intas Pharmaceuticals Ltd, Biotest AG, Octapharma Plasma, Kamada Ltd, SK Plasma Co. Ltd, Reliance Life Sciences, Bharat Serums And Vaccines Limited.

North America was the largest region in the prothrombin complex concentrate market in 2025. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prothrombin complex concentrate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the prothrombin complex concentrate market by increasing costs of imported plasma derivatives, recombinant factors, sterile manufacturing equipment, and cold-chain logistics components. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported PCC products, while Asia-Pacific faces pricing pressure on plasma-based exports. These tariffs are raising treatment costs and affecting supply availability. However, they are also supporting domestic plasma fractionation, regional manufacturing of coagulation products, and investment in local biopharmaceutical production capabilities.

The prothrombin complex concentrate market research report is one of a series of new reports that provides prothrombin complex concentrate market statistics, including prothrombin complex concentrate industry global market size, regional shares, competitors with a prothrombin complex concentrate market share, detailed prothrombin complex concentrate market segments, market trends and opportunities, and any further data you may need to thrive in the prothrombin complex concentrate industry. This prothrombin complex concentrate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prothrombin complex concentrate (PCC) is a therapeutic product that contains clotting factors and is used to prevent or treat bleeding in patients with coagulation disorders. It is administered intravenously to quickly replenish clotting factor levels in conditions such as hemophilia, warfarin reversal, and severe bleeding events.

The primary product types in the prothrombin complex concentrate market include 3-factor prothrombin complex concentrates (3F-PCC), 4-factor prothrombin complex concentrates (4F-PCC), and other related products. Three-factor prothrombin complex concentrates contain clotting factors II, IX, and X and are used to control bleeding without the addition of factor VII. These products are indicated for multiple clinical situations, including hemorrhagic episodes associated with factor IX deficiency (hemophilia B), trauma, acute life-threatening coagulopathy with active bleeding, warfarin-associated severe bleeding, and reversal of non-warfarin anticoagulants in the presence of acute bleeding. Routes of administration include intravenous, subcutaneous, and intramuscular injections, and they are used across hospitals, ambulatory surgical centers, specialty clinics, and other healthcare settings.

The prothrombin complex concentrate market consists of sales of activated PCC, recombinant coagulation factors, combination hemostatic agents, warfarin reversal, and emergency coagulation therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.